Antitumor effects of the antispermatogenic agent, 2,3-dihydro-2-(1-naphthyl)-4(1H)-quinazolinone (NSC-145669).
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001555:Benzene Derivatives / Q000627:therapeutic use; D002247:Carbon Isotopes; D002478:Cells, Cultured; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007659:Ketones / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy / Q000378:metabolism; D007942:Leukemia, Experimental / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D009281:Naphthalenes / Q000627:therapeutic use*; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009368:Neoplasm Transplantation; D009929:Organ Size; D011799:Quinazolines / Q000627:therapeutic use*; D011804:Quinolines / Q000627:therapeutic use; D012334:RNA, Neoplasm / Q000096:biosynthesis; D013997:Time Factors
D000970:Antineoplastic Agents; D001555:Benzene Derivatives; D002247:Carbon Isotopes; D004273:DNA, Neoplasm; D007659:Ketones; D009281:Naphthalenes; D009363:Neoplasm Proteins; D011799:Quinazolines; D011804:Quinolines; D012334:RNA, Neoplasm